Endocrine Abstracts

Objective: Anti-Müllerian hormone (AMH) has recently been evaluated as a marker for follicle reserve and as a new marker for ovarian function in women. In the male, it is produced in Sertoli cells (SC) in the testis. We evaluated serum levels of AMH as a marker of SC function and male fertility by comparing normo- and oligozoospermic men.Materials and methods: Serum levels of AMH were determined by enzyme immunoassay in two groups of men with normal...

Objective: C-reactive protein (CRP) is a nontraditional risk factor that predicts cardiovascular disease but its relationship between diabetes and insulin resistance is not well documented. We evaluated the association of CRP levels and insulin resistance in a group of patients at high risk for diabetes.Materials and methods: In this study we evaluated 22 first degree relatives of type 2 diabetic patients with impaired glucose tolerance test (Group 1) an...

Background: The presence of the metabolic syndrome (MS) increases cardiovascular morbidity and mortality but few data is available on the outcome in subjects with the MS and subclinical atherosclerosis.Aim: We aimed to assess cardio- and cerebro-vascular events in subjects with MS and subclinical atherosclerosis.Methods: We followed-up for 5 years 339 subjects with asymptomatic carotid intima-media thickness >0.9 mm, of whom 13...

Primary hyperparathyroidism (PHPT) negatively affects renal function. It is known that chronic kidney disease is a predictor of cardiometabolic diseases. Cystatin C (cystC), an alternative measure of renal function, has been associated with adverse cardiovascular events and cardiometabolic risk factors. This study was aimed to evaluate serum cystC, its relationships with PTH and cardiometabolic risk in patients with PHPT.The following parameters were mea...

Background: To arrest the immune-mediated destruction of the insulin-producing pancreatic beta cells in type 1 diabetes (T1D), interventional studies have predominantly focussed on two distinct approaches: arresting the ongoing immune response or protecting the pancreatic beta cells. Recently, both approaches using respectively low-dose anti-thymocyte globulin (ATG), an immune-depleting agent, and verapamil, a calcium channel blocker with beta cell protective ...

The high sensitivity C-reactive protein (hs-CRP), mediator of atherosclerotic disease, is known to be a sensitive predictor of coronary heart disease in type 2 diabetes mellitus (T2DM).Aims: To evaluate the relationship of hs-CRP levels to metabolic syndrome (MS) and albuminuria in T2DM.Methods: Four hundred and eighty-eight T2DM subjects were recruited. Patients with hs-CRP ≥10 mg/l, creatinine ≥1.4 mg/dl, chronic infl...

It has been demonstrated that everolimus, an mTOR inhibitor, has potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures. We aimed at evaluating the possible antiproliferative effects of everolimus in a group of 20 human MTC in primary culture. To this purpose, 20 MTCs were dispersed in primary cultures, treated without or with 1 nM – 1 μM everolimus, 10 nM SOM230, and/or 50 nM IGF1. Cell viab...

Parafollicular C-Cells represent 1% of thyroid cells and differ from follicular cells for their origin from the neural crest. At variance with follicular cells, their growth and function are independent from thyrotropin stimulating hormone (TSH), they do not take up iodine and they produce and secrete calcitonin (CT) but not thyroglobulin. C-Cell Hyperplasia (CCH) is defined as an increased number of normal C-cells (i.e. 50 or more C-cells in at least one low-power field (100&...

Bone metabolism can be measured indirectly with specific biochemical markers. Desoxypyridinolin (DPD) is a derivate of hydroxypyridinium, which is discharged by bone resorption and is totally excreted urinary. A further marker of collagen resorption is the c-terminal telopeptide of collagen type I, which is liberated to blood circulation within the bone’s degradation and undergoes renal elimination. The aim of our investigation was to look after a correlation of these par...

IntroductionBased on the evidence available back then, in 2015 we developed a provincial multicenter protocol for screening and follow up of no-index patients with SDHB and SDHC mutations.Objectives1. To evaluate the performance of the protocol designed for the follow-up of asymptomatic SDHB and C carriers. 2. To describe the penetrance of manifestations associated with hereditary PGL-FEO syndromes type 3 and...